Delgocitinib for chronic hand eczema: trial evidence

Delgocitinib is a topical Janus kinase inhibitor approved by the U.S. Food and Drug Administration in July 2025 for a defined group of adults with moderate to severe chronic hand eczema. The approval does not cover every hand rash. It applies when topical corticosteroids have produced an inadequate response or are not advisable [1][4].

Two vehicle-controlled phase 3 trials found higher clear-or-almost-clear response rates with delgocitinib at 16 weeks. A later head-to-head trial also favored the cream over oral alitretinoin on its prespecified severity outcome [2][3]. These results support an additional treatment option, but they do not mean that most users will have clear hands or that a topical JAK inhibitor has no important risks.

What condition did the FDA label cover?

Chronic hand eczema is a recurring or persistent inflammatory disorder of the hands and wrists. It can reflect more than one process, including irritant exposure, contact allergy, and an atopic tendency. Similar-looking disease can also come from infection, psoriasis, or other diagnoses. The drug label therefore cannot replace a diagnostic assessment.

The FDA indication is narrower than the everyday word eczema. It covers adults with moderate to severe chronic hand eczema after an inadequate response to topical corticosteroids, or when those drugs are not advisable [1]. It does not establish use for children, facial eczema, a brief irritant reaction, or an undiagnosed hand eruption.

The label describes delgocitinib as a topical pan-JAK inhibitor. Blocking JAK signaling can alter pathways involved in inflammation and itch. A plausible mechanism does not predict whether a particular person's disease is driven by the same pathway, whether an exposure is still occurring, or whether contact allergy needs separate investigation.

What did DELTA 1 and DELTA 2 find?

DELTA 1 and DELTA 2 were randomized, double-blind, vehicle-controlled trials in adults with moderate to severe chronic hand eczema. Together they enrolled 960 participants and compared delgocitinib cream 20 mg/g with its vehicle twice daily for 16 weeks [2]. The studies were funded by LEO Pharma, and several authors reported company roles or financial relationships.

The primary outcome was strict: hands had to be rated clear or almost clear at week 16, with at least a two-step improvement from baseline [2]. The results should be read as absolute response rates, not only as relative differences.

Both trials favored delgocitinib on the primary outcome [2]. They also show the limit of a headline such as “twice the response”: 71% to 80% of treated participants did not reach clear or almost clear status at week 16. Partial improvement can matter, but it is different from the primary endpoint.

Adverse events were reported by similar proportions of delgocitinib and vehicle recipients in the two trials. COVID-19 and nasopharyngitis were among the most frequent events [2]. Sixteen weeks is useful for comparing short-term groups, but it cannot answer uncommon or very long-term risks by itself.

What did the head-to-head trial add?

DELTA FORCE compared topical delgocitinib with oral alitretinoin in 513 adults with severe chronic hand eczema. The assessor-masked trial used change in the Hand Eczema Severity Index at week 12 as its primary outcome [3]. It was not a placebo comparison.

The adjusted mean severity reduction was greater with delgocitinib. Adverse events were reported in 49% of participants assigned to delgocitinib and 76% assigned to alitretinoin; headache accounted for much of the difference [3]. The sponsor was again LEO Pharma, and financial relationships were extensively disclosed.

This result is clinically useful, but it should not be generalized into a ranking of every hand-eczema treatment. The study compared two specified regimens in selected adults. It did not compare allergen avoidance, workplace modification, phototherapy, every topical anti-inflammatory option, or every systemic therapy.

What safety limits matter?

“Topical” does not mean “risk free.” The FDA prescribing information warns about serious infections and non-melanoma skin cancer, and it separately explains potential risks associated with JAK inhibition, including major cardiovascular events, thrombosis, and lipid changes [1]. Some of that context comes from experience with the drug class rather than frequent events seen in the hand-eczema trials. That distinction matters, but it does not make the warnings optional.

The label also limits the amount of cream and advises against combining it with other JAK inhibitors or potent immunosuppressants [1]. The correct interpretation is not that everyone needs the same testing or that no testing is needed. Medical history, infection risk, vaccination status, other medication, and the area being treated can change the discussion.

Persistent fissures, rapidly spreading redness, pus, fever, or significant pain may signal infection or another complication rather than ordinary dryness. Those findings need timely clinical assessment.

Questions the trials do not settle

The evidence leaves several practical gaps:

• Long-term effectiveness outside an extension-study setting remains less certain than the first 16 to 24 weeks.
• Vehicle-controlled trial results do not show which exposure, allergy, or occupation-related measures a person still needs.
• The FDA indication is for adults; pediatric results should not be imported into that label.
• Industry sponsorship and author financial relationships do not invalidate the data, but they support reading the prespecified outcomes and absolute rates closely.
• A treatment response does not confirm the original diagnosis.

The same principle applies across chronic hand eruptions: appearance alone may not identify the cause, and treatment response does not replace diagnostic reassessment.

Bottom line

Delgocitinib cream is an FDA-approved option for adults with moderate to severe chronic hand eczema when topical corticosteroids are inadequate or not advisable [1][4]. Two phase 3 trials showed better 16-week response than vehicle, and a separate head-to-head trial favored delgocitinib over oral alitretinoin on its prespecified severity measure [2][3].

The absolute results are more informative than a promotional summary. Between one fifth and just under one third of treated participants met the strict clear-or-almost-clear endpoint at week 16. Diagnosis, trigger control, label warnings, and individual risk still matter.

This article is for informational purposes and does not constitute medical advice. Chronic hand eczema should be diagnosed and treated with a qualified clinician.